Literature DB >> 18845609

Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization.

Jih-Shyong Lin1, Yih-Sharng Chen, Han-Sun Chiang, Ming-Chieh Ma.   

Abstract

Preconditioning, such as by brief hypoxic exposure, has been shown to protect hearts against severe ischaemia. Here we hypothesized that hypoxic preconditioning (HPC) protects injured hearts by mobilizing the circulating progenitor cells. Ischaemia-reperfusion (IR) injury was induced by left coronary ligation and release in rats kept in room air or preconditioned with 10% oxygen for 6 weeks. To study the role of erythropoietin (EPO), another HPC + IR group was given an EPO receptor (EPOR) antibody via a subcutaneous mini-osmotic pump 3 weeks before IR induction. HPC alone gradually increased haematocrit, cardiac and plasma EPO, and cardiac vascular endothelial growth factor (VEGF) only in the first two weeks. HPC improved heart contractility, reduced ischaemic injury, and maintained EPO and EPOR levels in the infarct tissues of IR hearts, but had no significant effect on VEGF. Interestingly, the number of CD34(+)CXCR4(+) cells in the peripheral blood and their expression in HPC-treated hearts was higher than in control. Preconditioning up-regulated cardiac expression of stromal derived factor-1 (SDF-1) and prevented its IR-induced reduction. The EPOR antibody abolished HPC-mediated functional recovery, and reduced SDF-1, CXCR4 and CD34 expression in IR hearts, as well as the number of CD34(+)CXCR4(+) cells in blood. The specificity of neutralizing antibody was confirmed in an H9c2 culture system. In conclusion, exposure of rats to moderate hypoxia leads to an increase in progenitor cells in the heart and circulation. This effect is dependent on EPO, which induces cell homing by increased SDF-1/CXCR4 and reduces the heart susceptibly to IR injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845609      PMCID: PMC2655408          DOI: 10.1113/jphysiol.2008.160887

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  48 in total

Review 1.  Invited review: Adaptive responses of skeletal muscle to intermittent hypoxia: the known and the unknown.

Authors:  T L Clanton; P F Klawitter
Journal:  J Appl Physiol (1985)       Date:  2001-06

Review 2.  HIF-1: mediator of physiological and pathophysiological responses to hypoxia.

Authors:  G L Semenza
Journal:  J Appl Physiol (1985)       Date:  2000-04

3.  Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction.

Authors:  Giuseppina Milano; Antonio F Corno; Silvio Lippa; Ludwig K Von Segesser; Michele Samaja
Journal:  Exp Biol Med (Maywood)       Date:  2002-06

Review 4.  Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms.

Authors:  N R Prabhakar
Journal:  J Appl Physiol (1985)       Date:  2001-05

5.  Intermittent high altitude hypoxia inhibits opening of mitochondrial permeability transition pores against reperfusion injury.

Authors:  Wei-Zhong Zhu; Yan Xie; Le Chen; Huang-Tian Yang; Zhao-Nian Zhou
Journal:  J Mol Cell Cardiol       Date:  2005-11-08       Impact factor: 5.000

6.  Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells.

Authors:  K A Jackson; S M Majka; H Wang; J Pocius; C J Hartley; M W Majesky; M L Entman; L H Michael; K K Hirschi; M A Goodell
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

8.  Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.

Authors:  Arman T Askari; Samuel Unzek; Zoran B Popovic; Corey K Goldman; Farhad Forudi; Matthew Kiedrowski; Aleksandr Rovner; Stephen G Ellis; James D Thomas; Paul E DiCorleto; Eric J Topol; Marc S Penn
Journal:  Lancet       Date:  2003-08-30       Impact factor: 79.321

9.  Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury.

Authors:  Zheqing Cai; Dominador J Manalo; Guo Wei; E Rene Rodriguez; Karen Fox-Talbot; Huasheng Lu; Jay L Zweier; Gregg L Semenza
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

10.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4.

Authors:  Isabelle Petit; Martine Szyper-Kravitz; Arnon Nagler; Meir Lahav; Amnon Peled; Liliana Habler; Tanya Ponomaryov; Russell S Taichman; Fernando Arenzana-Seisdedos; Nobutaka Fujii; Judith Sandbank; Dov Zipori; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2002-06-17       Impact factor: 25.606

View more
  14 in total

1.  Erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.

Authors:  Hye Yeong Nam; Youngsook Lee; Minhyung Lee; Sug Kyun Shin; Tae-il Kim; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2011-10-20       Impact factor: 9.776

Review 2.  Preconditioning strategy in stem cell transplantation therapy.

Authors:  Shan Ping Yu; Zheng Wei; Ling Wei
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

Review 3.  Oxidative stress: Biomarkers and novel therapeutic pathways.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

4.  Autologous peripheral blood-derived mononuclear cells induced by erythropoietin improve critical ischemic limbs.

Authors:  Tamotsu Kanbara; Hirotsugu Kurobe; Takashi Kitaichi; Mikio Sugano; Taisuke Nakayama; Hajime Kinoshita; Takashi Iwase; Masafumi Akaike; Masahiro Abe; Masataka Sata; Toshio Matsumoto; Tetsuya Kitagawa
Journal:  Ann Vasc Dis       Date:  2012-02-15

5.  Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke.

Authors:  Hon-Kan Yip; Tzu-Hsien Tsai; Hung-Sheng Lin; Shu-Fang Chen; Cheuk-Kwan Sun; Steve Leu; Chun-Man Yuen; Teng-Yeow Tan; Min-Yu Lan; Chia-Wei Liou; Cheng-Hsien Lu; Wen-Neng Chang
Journal:  Crit Care       Date:  2011-01-26       Impact factor: 9.097

6.  Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin.

Authors:  Kuo-Ho Yeh; Tzu-Hsien Tsai; Han-Tan Chai; Steve Leu; Sheng-Ying Chung; Sarah Chua; Yung-Lung Chen; Hung-Sheng Lin; Chun-Man Yuen; Hon-Kan Yip
Journal:  J Transl Med       Date:  2012-01-05       Impact factor: 5.531

7.  Perspectives on: SGP symposium on mitochondrial physiology and medicine: mitochondrial proteome design: from molecular identity to pathophysiological regulation.

Authors:  Jun Zhang; Amanda Lin; Jared Powers; Maggie P Lam; Christopher Lotz; David Liem; Edward Lau; Ding Wang; Ning Deng; Paavo Korge; Nobel C Zong; Hua Cai; James Weiss; Peipei Ping
Journal:  J Gen Physiol       Date:  2012-06       Impact factor: 4.086

Review 8.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02

9.  TRPV1 Hyperfunction Contributes to Renal Inflammation in Oxalate Nephropathy.

Authors:  Chien-Lin Lu; Te-Yi Teng; Min-Tser Liao; Ming-Chieh Ma
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

10.  Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats.

Authors:  Jing Lu; Yu-yu Yao; Qi-ming Dai; Gen-shan Ma; Shu-feng Zhang; Lei Cao; Li-qun Ren; Nai-feng Liu
Journal:  Cardiovasc Diabetol       Date:  2012-09-07       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.